| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
(-)-Asarinin targets multiple pathways. It induces apoptosis by promoting mitochondrial ROS accumulation and inhibiting the STAT3 signaling pathway. It is a Src family kinase inhibitor that suppresses mast cell activation. It is also a non-competitive ΔS-desaturase inhibitor with a Ki of 0.28 mM.
|
|---|---|
| ln Vitro |
In vitro, (-)-asarinin induces apoptosis in cancer cells and precancerous cells. It promotes mitochondrial ROS accumulation and inhibits the STAT3 signaling pathway. It suppresses mast cell activation as a Src family kinase inhibitor. The compound also possesses anti-viral, anti-allergic, anti-tuberculous, and anti-tumor effects.
|
| ln Vivo |
In vivo activity of (-)-asarinin has not been extensively characterized in animal models. The compound has demonstrated various biological activities in vitro, but specific in vivo efficacy data are limited. It possesses pain relief and anti-tumor effects.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for (-)-asarinin may involve studying its inhibition of Src family kinases or ΔS-desaturase. These assays typically use purified enzymes and measure the compound's ability to inhibit their activity, determining parameters such as Ki values.
|
| Cell Assay |
In vitro cell-based assays for (-)-asarinin typically employ cancer cell lines. Cells are treated with the compound, and endpoints such as apoptosis (Annexin V/PI staining), ROS accumulation (fluorescent probes), and STAT3 signaling (Western blot) are assessed.
|
| Animal Protocol |
In vivo animal studies with (-)-asarinin have not been extensively reported. No specific animal models have been described in the available literature. The compound is primarily studied in vitro for its various biological activities.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of (-)-asarinin have not been characterized. No absorption, distribution, metabolism, or excretion studies have been reported. The compound is a natural product lignan with potential therapeutic applications.
|
| Toxicity/Toxicokinetics |
The toxicity profile of (-)-asarinin has not been extensively characterized. The compound is a natural product and is generally considered to have low toxicity, but specific toxicology data are not available. It is intended for research use only.
|
| References | |
| Additional Infomation |
According to reports, (-)-asarin exists in Aristolochia debilis, Aconitum carmichaelii, and other organisms for which data are available.
(-)-Asarinin is a research-grade natural product extracted from Asarum sieboldii Miq. It exhibits various biological activities, including anti-tumor, anti-viral, anti-allergic, and anti-tuberculous effects. The compound is not an approved therapeutic drug and has no clinical trial history. It is supplied as a white powder with a purity of >98%. |
| Molecular Formula |
C20H18O6
|
|---|---|
| Molecular Weight |
354.3533
|
| Exact Mass |
354.11
|
| CAS # |
133-04-0
|
| PubChem CID |
11869417
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
504.4±50.0 °C at 760 mmHg
|
| Melting Point |
121ºC
|
| Flash Point |
212.3±30.0 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.623
|
| LogP |
3.32
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
26
|
| Complexity |
482
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1[C@@H]2[C@@H](CO[C@@H]2C3=CC4=C(C=C3)OCO4)[C@@H](O1)C5=CC6=C(C=C5)OCO6
|
| InChi Key |
PEYUIKBAABKQKQ-FQZPYLGXSA-N
|
| InChi Code |
InChI=1S/C20H18O6/c1-3-15-17(25-9-23-15)5-11(1)19-13-7-22-20(14(13)8-21-19)12-2-4-16-18(6-12)26-10-24-16/h1-6,13-14,19-20H,7-10H2/t13-,14-,19-,20+/m1/s1
|
| Chemical Name |
5-[(3R,3aS,6S,6aS)-3-(1,3-benzodioxol-5-yl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-6-yl]-1,3-benzodioxole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~282.21 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (7.06 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.06 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8221 mL | 14.1103 mL | 28.2207 mL | |
| 5 mM | 0.5644 mL | 2.8221 mL | 5.6441 mL | |
| 10 mM | 0.2822 mL | 1.4110 mL | 2.8221 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
